Unknown NA INTERVENTIONAL 2-arm NCT03005314

Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer

Sponsor: Shandong Cancer Hospital and Institute

Conditions Esophageal Cancer TNM Staging Primary Tumor (T) T3

Updated 6 times since 2017 Last updated: Jan 17, 2018 Started: Aug 31, 2016 Primary completion: Dec 31, 2018 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Esophageal Cancer TNM Staging Primary Tumor (T) T3, this trial is ongoing. The trial is conducted by Shandong Cancer Hospital and Institute and has accumulated 6 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Feb 2020 — Jan 2021 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2020 [monthly]

Recruiting NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting NA

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong Cancer Hospital and Institute
The Second Hospital of Shandong University
Wuhan YZY Medical Science and Technology Co., Ltd.

Data source: The Second Hospital of Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China